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ABSTRACT 
Objectives: The aim of present investigation was formulation development and evaluation of bi-layer tablets of citicoline sodium. Materials and 
Methods: An aqueous granulation process was adopted to formulate citicoline sodium (CTS) bilayer tablets. Wet granulation method has been 
utilized for the formulation of bilayer CTS tablet. Citicoline sodium, microcrystalline cellulose (pH 101 & 102), HPMC K4, K15, K-100, PVP K-30, 
Magnesium stearate, cross-carmellose sodium, sodium starch glycolate and red oxide were used for preparation. Pre-formulation studies of 
citicoline sodium and drug excipient compatibility study was carried to optimize the formulation variables. Two layers, immediate release (IR 
layer) and sustained release (SR) has been developed and evaluated for the various parameters e.g. micromeritic properties, percentage yield, 
particle size, hardness, thickness, weight variation, percent friability and percent assay,  In-vitro dissolution and In-vitro release studies. Result 
and Discussion: Pre-formulation study of citicoline sodium denotes that evaluated parameters confirm the suitability and compliance of drug 
with polymers.  Drug excipient compatibility study through the DSC confirmed that polymer, excipient and drug were compatible with each other 
and no incompatibility issue found during the preparation of formulation. FT-IR study is also executed to confirm the drug-excipient 
incompatibility. In all physical mixtures of drug and polymer, there was neither masking of single characteristic peak nor existence of additional 
peak in drug spectra; this has proven that drug and polymers are compatible with each other. Hardness 10-11 kg/cm2, thickness 7.3-7.4 mm, 
percent weight variation 1.2%, friability 0.1-0.3%, assay was 99-101% denotes the successful development of CTS tablets. Conclusion: These all 
parameters denote that the formulation has optimized, evaluated and were in the standard range. Hence, this optimized bilayer tablet 
formulation could be a potential formulation to promote sustained release, promote delivery of drugs from a single dosage form to improve 
patient compliance and give better disease management. 
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INTRODUCTION 
Conventional oral dosage form has many disadvantages 
includes high frequency of dosing, drug dependency and side 
effects. Usually conventional dosage form produces wide 
range fluctuation in drug concentration in blood stream and 
tissues with consequent undesirable toxicity and poor 
efficiency. The factor such as repetitive dosing and 
unpredictable absorption led to the concept of controlled 
and sustained drug delivery systems. Sustained-release and 
controlled dosage forms are designed to release drug at a 
pre-determined rate in order to maintain a constant drug 
concentration for a specific period of time with minimum 
side effects1.  
The goal in designing sustained or controlled delivery 
systems is to reduce the frequency of the dosing or to 
increase effectiveness of the drug by localization at the site of 
action, reducing the dose required or providing uniform drug 
delivery. The primary objective of sustained release drug 
delivery is to ensure safety and to improve efficacy of drugs 
as well as patient compliance2. In this era the interest is 
increased in development of controlled releases formulation 
with aim to reduce frequency of dosing/dose, improve the 
patient compliances, minimized dose dependent side effects 
and prolong the circulation period of the drugs.  
Now a day multilayer tablet dosage form shows great 
acceptability. Multilayer tablet are bi-layer, tri-layer and four 
layer tablets3. Mainly bi-layer tablet is the new era for the 
successful development of controlled release formulation. Bi-
layer tablet is single dosage form with combination of two or 
more active pharmaceutical ingredients (API) which 
promoting patient convenience compliance and reduce the 
dose frequency4. Bi-layered tablet is suitable for sequential 
release of two drugs in combination and separate by two 
compatible substances and bilayer tablet has advantageous 
in which one layer is immediate release as initial dose and 
second layer is maintenance dose5. In the case of bi-layered 
tablets drug release can be rendered almost unidirectional if 
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the drug can be incorporated in the upper non-adhesive 
layer its delivery occurs into the whole oral cavity6.  
Citicoline sodium is also known as cytidine Diphosphate-
choline (cdp-choline) and cytidine 5’diphosphocholine7. 
Citicoline is often called a “brain nutrient” because it 
increases levels of several important neuro-transmitters 
including acetylcholine, dopamine and Noradrenalin. It helps 
to maintain the integrity of neuronal cell membranes and 
increases energy production in the frontal cortex. In the US, 
Citicoline is marketed as a dietary supplement8. Citicoline 
protects cholinergic neurons from auto cannibalism, a 
process in which membrane phospholipids are catabolised to 
provide choline for synthesis of acetylcholine. This occurs 
when choline supplies are depleted, necessitating sacrifice of 
membrane phospholipids to maintain neurotransmission. As 
an exogenous source of choline for acetylcholine production, 
Citicoline thus spares membrane phospholipids (in 
particular, phosphatidyl choline) and prevents neuronal cell 
death. It is also used in Alzheimer disease and Parkinson’s 
disease. 
Various techniques for bi-layer tablet are nowadays in 
marketed includes OROS® push pull technology system 
consist of mainly two or three layer. L-OROSTM technology 
used for the solubility problem in that case Alza  developed 
L-OROS system, where a lipid soft gel product contain drug 
in dissolved state and coated with first a barrier membrane, 
second with osmotic push layer and  third with semi-
permeable membrane and drilled with an exit orifice9. 
DUROS technology consists an outer cylindrical titanium 
alloy reservoir. This reservoir has high impact strength and 
protects the drug molecules from enzymes. The DUROS 
technology is the miniature drug dispensing system that 
opposes like a mini syringe and release minute quantity of 
concentrated form in continues and consistent over an 
months or year.  
EnSotrol technology10 and  Elan drug technologies is the dual 
release drug delivery system (DUREDAS™ Technology), 
which provide immediate or sustained release of two drugs 
or different release rates of the same drug in one dosage 
form. The tab letting process can provide an immediate 
release granulate and a modified-release hydrophilic matrix 
complex as separate layers within the one tablet. The 
modified-release properties of the dosage form are provided 
by a combination of hydrophilic polymers. These techniques 
encourage the formulation development of the citicoline 
sodium bi-layered sustained released formulation. 
The aim of the present paper is the formulation development 
of sustained released bi-layer tablets of citicoline sodium and 
characterized for their sustained release credential. 
MATERIALS AND METHODS 
Citicoline Sodium was procured from Euticals spa, Italy. 
Microcrystalline Cellulose (pH 101 & 102) was obtained 
from N.B. Enterprise, Gujarat, India. HPMC K4M, HPMC K15 
M, HPMC K-100 M were procured from color con Asia Private 
Ltd, Mumbai, India, PVP K-30 was purchased from Shital 
Chemicals Ltd, Gujarat, India. Magnesium Stearate was 
procured from Sunshine Organics Pvt. Ltd, Gujarat, India, 
Cross carmellose sodium and sodium starch glycolate were 
purchased from SD Fine Chemicals Ltd., Mumbai, India and 
Red oxide was purchased from Hindustan Mineral Products 
Company Ltd. Mumbai. All the chemical were analytical 
grade. 
Calibration curve for API 
The calibration curve of CTS has been prepared by dissolving 
the CTS in distilled water11.  
Preparation of standard solution 
Weight accurately about 1000 mg of Citicoline sodium 
(working standard) in a 100 ml volumetric flask, add 
sufficient water, sonicate to dissolve and make up the 
volume with water and mix. Dilute 1 ml of this solution to 
100 ml with water and filter the solution through what-man 
filter paper no. 42. Make the dilution of concentration of 10, 
15, 20, 25, 30, 35, 40, 45 and 50µg/ml.  
Sample preparation for assay 
Weight accurately 1000 mg of Citicoline sodium by mixing 
content of 20 crushed tablets, taken into a 500 ml volumetric 
flask and add 300 ml of distilled water, sonicate to dissolve 
and make the volume up to 500 ml with water and mix. 
Centrifuge the solution for 5 min and filter the solution 
through what-man filter paper No. 42. Further dilute 1 ml of 
the filtrate to 100 ml with water. Absorbance were taken at 
272 nm on UV spectrophotometer (1800, Shimdzu UV).  
Preparation of tablets 
Citicoline sodium (CTS) tablet was prepared by the 
granulation process. Two layers, Immediate release (IR) and 
sustained release (SR) layer has been prepared for the 
formulation of the bi-layer tablets.  
Manufacturing process for immediate release layer 
In the preparation of the IR layers, firstly citicoline sodium 
passed through the 20# mesh security sieve (S.S.). Avicel PH 
102, PVP K 30 and Ac-di-sol passes through 40#, and Red 
oxide of iron shifted through 100#. Mix the material in rapid 
mixer granulator for 10 min at slow speed and after proper 
mixing purified water was added slowly to the dry mix and 
then granulates the materials; add additional quantity of 
purified water, if required. Granulate for 6-8 min with 
impeller and chopper at slow speed and for 2 min at fast 
speed.  
Dry the granules in the fluid bed dryer pass the wet mass 
through 3 mm screen using Cad mill & then dry the granules 
in FBD keeping 75-85 °C as the inlet temperature and outlet 
temperature ranges 55°C to 65°C. Dry the granules till the 
LOD is between 3.0–4.0% determined at 105 °C for 5 min on 
IR moisture balance. Pass the dried granules through 16#. 
Pass retained granules through 1.8/1.0 mm S.S., knives 
forward at slow speed of cad mill and again pass through 
16#. Sift Magnesium stearate through 40# and mixed with 
dried granules in Cage blender for 10 min at 13±2 RPM 
speed. Different batches of the IR layer has been formulated 
and evaluated by the various parameters.  
Manufacturing process for sustain release (SR) layer 
Same procedure adopted for the SR layer as discuss in IR 
layer preparation, only HPMC K100M, was used in the place 
of PVP K 30 and Ac-di-sol. Different batches of the SR layer 
has been formulated and evaluated by the various 
parameters. 
Preparation method of bilayer tablet 
Compress the IR and SR Layers  
In that first SR layer compress by the tablet compression 
machine using an optimum size 21.5×10.5 mm shape punch 
and adjust the die fill weight 1210±5.0%. Compression was 
operates using up to optimum hardness up to 4 kg/cm2 and 
then after IR layer granules was put inside the die and 
commence the regular compression. Twenty tablets were 
evaluated for the various parameters. Weight variation was 
checked for in-process evaluation by using electronic 
balance. Eight batches has been prepared (A1 –A8) and 
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evaluated for different parameters. Tablet hardness was 
evaluated by using hardness tester (Monsanto tester). 
Friability determined by the Roche friabilator for 5 min at a 
speed of 25 rpm/min. The thickness and diameter of the 
tablets were measured by vernier caliper scale12. 
Apparatus used for the manufacturing, in-process evaluation 
and preliminary testing and evaluation of the finished 
product (bilayer tablets), includes digital balance, electronic 
weighing balance (Shimadzu, Tokyo, Japan), UV-Visible 
spectrophotometer (Shimadzu 1700), sonicator (Bransone 
Ultrasonic), Digital pH meter (Thermo Orion), Hot air oven, 
Bulk/tapped density apparatus (Expo Hi-Tech), Rotary 
compression machine (Cadmac), Thickness tester, Monsanto 
Hardness Tester, Friabilator (Electro lab), disintegration test 
apparatus and dissolution test apparatus (Electro lab), FTIR-
8400 S and Humidity chamber, Environment test chamber 
(Expo Hi-Tech).   
Evaluation of bi-layer tablets 
Tablet thickness and size 
Vernier caliper was used for measurement of thickness and 
diameter. These parameters are important for uniformity of 
tablet size13. 
Weight variation test 
To study weight variation 20 tablets of the formulation were 
weighed using a electronic weighing balance (Shimadzu, 
Tokyo, Japan) and the test was performed according to the 
official method. As per I.P. weight variation should not more 
than 5 percent14. 
Uniformity of weight 
Twenty tablets were selected at random and the average 
weight was calculated. Weight Variation was calculated and 
was compared with I. P. standards15. 
Drug content 
Twenty tablets were weighed individually, and the drug was 
extracted in water. The range of content uniformity is 90-
110 percent16. 
Hardness 
Hardness denotes as an important indicator for tablet 
strength, for shipping or breakage under conditions of 
storage, transportation and handling before usage. The 
resistance of tablets hardness measured with hardness 
tester i.e. mainly by Monsanto Hardness tester. 
The unit for hardness is kg/cm2. The hardness of 20 tablets 
was determined using the Monsanto hardness tester and the 
average values were calculated17. 4 kg/cm2 is considered to 
be minimum for a satisfactory tablet16.  
Thickness 
The thickness of the tables was determined by using vernier 
calipers. 20 tablets were used and average values were 
calculated. This procedure has repeated in triplicate. 
Friability 
Friability is an indicator for tablet strength. The friability of 
the tablets was measured in a Roche friabilator. Twenty 
tablets were weighed accurately and placed in the tumbling 
apparatus that revolves at 25 rpm and dropping the tablets 
through a distance of six inches height with each 
revolution15. In after 4 min, the tablets were weighed and 
percentage friability was calculated from the loss in weight 
as given in equation as below. The weight loss should not be 
more than 1 %. This procedure has repeated in triplicate. 
% loss= [(Initial wt. of tablets – Final wt. of tablets)/Initial 
wt. of tablets] ×100. 
Disintegration test 
The disintegration test was carried out by use of 
disintegration test apparatus. Six tablets were subjected for 
analyzed in the apparatus and calculate the disintegration 
time and average value was calculated. 
In-vitro drug release study 
In-vitro drug release study was performed by using 
dissolution apparatus. These studies are carried out using 
USP dissolution test apparatus I at 100 rpm, 37±0.5°C, and 
pH 1.2 buffer (900 ml) (i.e. 0.1 N HCl) for 2 hrs (average 
gastric emptying time is 2 hrs) in simulated gastric or 
intestinal fluids are used. Experiment continued for another 
10 hours with pH 6.8 phosphate buffer (900ml) as the 
dissolution medium. 5ml of the samples were withdrawn 
and replaced with 5ml of drug-free dissolution medium at 
different time intervals. The samples withdrawn were 
analyzed by using UV spectrophotometer15,18. 
Characterization of bilayer tablet 
1. Particle size distribution 
There are number of methods for measuring particle size. 
Mostly sieving method used for measuring particle size 
distribution. 
Pre Compression parameter 
Physical Properties of Tablets 
Pre compression parameter of bilayer tablets were evaluated 
for bulk density, tapped density, Hausner’s ratio, angle of 
repose and Carr’s index. This Define the Physical properties 
of the formulation. 
Bulk density19 
Both loose bulk density (LBD) and tapped bulk density 
(TBD) were determined by transferring the accurate 
weighed amount of sample in 50 ml measuring cylinder, the 
granules without any agglomerates and measured the 
volume of packing and tapped 50 times on a plane surface 
and tapped volume of packing recorded and LBD and TBD 
calculated by following formula. 
     
               
                 
           
               
                        
 
Hausner’s ratio  
Hausner’s ratio is computed by applying the next equation 
Hausner’s ratio= Tapped density/ Bulk density 
Percentage compressibility index20 
Percentage compressibility of powder mix was determined 
by Carr’s Compressibility Index calculated by following 
formula.  
% Carr’s Index= (TBD-LBD) ×100/TBD;  
Where, TBD= Tapped bulk density; LBD= Loose bulk density. 
Angle of repose  
The frictional forces in loose powder or granules can be 
measured by the angle of repose. This is the maximum angle 
possible between the surface of a mass of powder or 
granules and the horizontal plane. Angle of repose is 
calculated by applying the next equation; 
tan θ = h/r; θ=tan-1(h/r), where θ=angle of repose; 
h=height; r=radius. 
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RESULT AND DISCUSSION 
Pre-formulation study of drug citicoline sodium (CTS) was 
performed and result indicates that CTS was freely soluble in 
water, 0.1N HCl, acetate buffer (pH 4.5) and soluble in 
phosphate buffer (pH 6.8 and pH 7.5).  Standard curve of 
citicoline sodium was depicted in Figure 1. Regression value 
was 0.999. Drug excipient compatibility study also carried by 
the Differential scanning colorimetric spectroscopy and 
indicates that the drug and excipient were compatible with 
each other.  For the DSC Study the peak of the CTS was found 
at 197°C and in the formulation, there was no significant 
change in endothermic peak is observed when it was mixed 
with the other excipient (Figure 2, 2A-2E) and FT-IR spectra 
also indicates that no extra peak has been generated that 
reflects that drug and all other excipient were compatible 
with each other. In all physical mixtures of drug and 
polymer, there was neither masking of single characteristic 
peak nor existence of additional peak in drug spectra, so we 
can prove that drug and polymers are compatible with each 
other.   
 
Figure 1: Standard curve of citicoline sodium
 
 
 
Figure 2: DSC thermogram of Citicoline sodium (CTS); (A) DSC thermo gram of CTS, (B) DSC thermo gram of CTS with HPMC K 
100 M; (C) Citicoline sodium with MCC, (D) Citicoline sodium with magnesium stearate, (E) Citicoline sodium with all excipient. 
 
Table 1: Pre-formulation study of optimized batch of IR layer 
Properties IR 1 IR 2 IR 3 IR 4 IR 5 IR 6 IR 7 IR 8 
Bulk density 
(gm/ml) 
0.46± 
0.12 
0.51± 
0.11 
0.42± 
0.13 
0.49± 
0.10 
0.42± 
0.11 
0.41± 
0.13 
0.41± 
0.12 
0.40± 
0.15 
Tapped density 
(gm/ml) 
0.46± 
0.13 
0.52± 
0.14 
0.43± 
0.12 
0.52± 
0.11 
0.44± 
0.10 
0.41± 
0.12 
0.42± 
0.14 
0.48± 
0.15 
Carr’s Index 9.2± 
0.25 
9.5± 
0.31 
9.6± 
0.26 
8.9± 
0.31 
9.3± 
0.24 
8.9± 
0.21 
9.2± 
0.18 
9.3± 
0.28 
Hausner’s ratio 1.1± 
0.26 
1.11± 
0.27 
1.01± 
0.19 
1.12± 
0.28 
1.11± 
0.25 
1.12± 
0.31 
1.12± 
0.24 
1.11± 
0.18 
Angle of repose 32.45± 
0.78 
31.2± 
0.85 
32.41± 
0.87 
28.43± 
0.78 
30.28± 
0.78 
31.21± 
0.78 
28.44± 
0.78 
28.0± 
0.78 
Disintegration 
time (min.) n=6 
3.58± 
0.10 
2.87± 
0.18 
1.52 
±0.12 
0.89± 
0.10 
4.23± 
0.10 
3.78± 
0.14 
2.89± 
0.12 
1.23± 
0.10 
*n=6, mean ± SD 
y = 0.015x + 0.0003  
R² = 0.999 
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Table 2: Pre-formulation study of optimized batch of SR layer 
Properties IR 1 IR 2 IR 3 IR 4 IR 5 IR 6 IR 7 IR 8 
Bulk density 
(gm/ml) 
0.438± 
0.012 
0.425± 
0.009 
0.416 
±0.007 
0.416± 
0.009 
0.408± 
0.010 
0.408± 
0.010 
0.400± 
0.011 
0392± 
0.012 
Tapped 
density 
(gm/ml) 
0.500± 
0.013 
0.488± 
0.014 
0.476± 
0.009 
0.476± 
0.008 
0.476± 
0.011 
0.465± 
0.012 
0.454± 
0.009 
0.454± 
0.010 
Carr’s Index 12.40± 
0.018 
12.40±0.0
18 
12.60±0.0
15 
10.71±0.0
16 
12.60±0.
018 
12.26±0.01
6 
12.25±0.01
2 
11.89±0.01
0 
Hausner’s 
ratio 
1.141±  
0.018 
1.148± 
0.017 
1.144± 
0.015 
1.120± 
0.016 
1.144± 
0.019 
1.40± 
0.016 
1.139± 
0.018 
1.138± 
0.009 
Angle of 
repose 
32.45± 
0.68 
29.47± 
0.58 
28.44± 
0.65 
32.37± 
0.66 
30.25± 
0.64 
28.00± 
0.58 
28.44± 
0.59 
28.0± 
0.56 
Disintegratio
n time min.) 
n=6 
1.68± 
0.12 
2.37± 
0.16 
2.02± 
0.14 
2.45± 
0.10 
3.32 ± 
0.10 
3.78± 
0.14 
2.89± 
0.12 
1.23± 
0.10 
*n=6, mean ± SD 
 
Table 3: Value of Hardness, thickness, percent friability, weight variation and percent assay batches IR1-IR8 (mean±SD, 
n=6) 
Batch No. Hardness Thickness Weight 
variation 
Percent 
Friability 
Percent assay 
IR1 11±0.25 7.3±0.18 1544±15.20 0.25±0.005 99.4±2.12 
IR 2 10.5±0.23  7.4±0.17 1540±10.14 0.14±0.004 99.5±2.15 
IR 3 10.5±0.19 7.3±0.17 1542±16.24 0.23±0.005 100.6±2.36 
IR 4 10.5±0.21 7.3±0.12 1541±20.25 0.18±0.003 101.4±1.98 
IR 5 11.0±0.20 7.3±0.15 1542±20.20 0.25±0.002 100.4±1.78 
IR 6 10.5±0.25 7.3±0.13 1540±19.36 0.25±0.005 99.2±2.14 
IR 7 11.0±0.24 7.3±0.16 1542±14.20 0.33±0.005 100.5±2.12 
IR 8 11.0±0.19 7.3±0.18 1545±18.20 0.21±0.007 99.8±3.12 
*n=6, mean ± SD 
 
Pre-formulation study of optimized batch of IR layer was 
enclosed in Table 1. The IR4 batch has shown fast 
disintegration time as compare with other batches. So it has 
confirmed that the concentration the Ac-Di-sol and MCC, was 
affect the release of drug content form IR layer and 
optimized for better disintegration. Preformulation of the 
IR4 tablet has showed the good flow property among all 
other batch of the IR layer tablets. Table 5 showed the 
different dissolution efficiency of the IR layer, in which the 
maximum dissolution efficiency of IR4 is 32.15, compared 
with the other batch of tablets and also shown highest drug 
release 98.18% at 20 min which was selected further for the 
optimization of the bi-layer tablets. These parameters were 
optimized by different trial of the bi-layer tablets. Evaluation 
of IR layer batches IR1-IR8 batches was shown in Table 3. 
  
Table 4: Value of Hardness, Thickness, percent friability, percent assay and Weight variation of Batches SR1-SR8 (mean 
± SD, n=6) 
Batch No. Hardness Thickness Weight variation Percent Friability Percent assay 
SR1 10.0±0.01 7.4±0.14 1212±20.15 0.20±0.006 99.2±2.5 
SR 2 10.5±0.02  7.3±0.12 1211±15.23 0.23±0.004 98.8±3.1 
SR 3 11.0±0.02 7.3±0.13 1212±18.58 0.16±0.006 99.7±2.9 
SR 4 11.0±0.01 7.4±0.12 1210±19.85 0.22±0.007 101.2±3.2 
SR 5 10.5±0.01 7.4±0.15 1213±21.25 0.37±0.005 99.4±2.8 
SR 6 10.0±0.02 7.4±0.12 1209±18.98 0.21±0.006 99.2±2.7 
SR 7 11.0±0.01 7.3±0.11 1210±19.84 0.30±0.007 100.7±2.5 
SR 8 11.0±0.01 7.3±0.12 1212±11.85 0.24±0.007 99.8±3.2 
*n=6, mean ± SD 
 
The SR1-SR8 batches were prepared by using different 
concentration of Avicel PH102, HPMC K4M, HPMC K15M and 
HPMC K100 by using water as a solvent for the granulation. 
In all batches (SR1-SR8), SR8 batch has good flow property 
and compressibility. Pre-formulation study of optimized 
batch of SR layer was enclosed in Table 2. In the SR1-SR3 
HPMC K4M was used and SR4-SR6 HPMC K15M was used 
but the drug release was not found as per in-house 
specification. In preparation of SR7-SR8 layers HPMC K100M 
was used promote the drug release profile as per the in-
house limitation. Evaluation of SR layer batches SR1-SR8 
batches was shown in Table 4.  
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Table 5: Pre-formulation study of batch A1-A8 (bilayer tablet) 
Properties IR 1 IR 2 IR 3 IR 4 IR 5 IR 6 IR 7 IR 8 
Bulk density 
(gm/ml) 
0.392± 
0.008 
0.392± 
0.009 
0.392 
±0.008 
0.385± 
0.010 
0.385± 
0.011 
0.377± 
0.008 
0.377± 
0.010 
0.377± 
0.009 
Tapped density 
(gm/ml) 
0.465± 
 0.013 
0.468± 
0.014 
0.454± 
0.009 
0.456± 
0.008 
0.476± 
0.011 
0.444± 
0.008 
0.454± 
0.013 
0.434± 
0.011 
Carr’s Index 15.70± 
0.35 
13.66± 
0.45 
13.66± 
0.41 
15.20± 
0.38 
15.20± 
0.41 
15.09± 
0.39 
15.09± 
0.51 
15.70± 
0.45 
Hausner’s ratio 1.186±  
0.024 
1.158± 
0.023 
1.158± 
0.019 
1.179± 
0.024 
1.177± 
0.019 
1.179± 
0.032 
1.177± 
0.042 
1.151± 
0.035 
Angle of repose 23.1± 
0.68 
24.76± 
0.75 
27.13± 
0.65 
27.10± 
0.58 
26.90± 
0.72 
27.50± 
0.69 
28.12± 
0.73 
28.0± 
0.64 
n=6, mean ± SD 
In-vitro dissolution profile of IR layer IR1-IR8 batches was 
shown in Figure 3. The comparative dissolution profile 
shown in table 26, Release profile of SR8 follows dissolution 
profile percent limit as per in-house limitation. From the 
above all trial batches, SR8 was optimized and it was used 
for the further study for the development of the bi-layer 
tablets.  
In-vitro release profile of SR layer depicted in Figure 4. 
Bilayer tablets have been prepared by wet compression 
method A1-A8. The comparative dissolution profile of A1-A8 
was shown in Table 7. 
 
Figure 3: Drug dissolution profile of various developed formulations (IR1-IR8). 
Table 6: Value of Hardness, Thickness, Diameter and Weight variation of batches A1-A8 
Batch No. Hardness* Thickness* Weight 
variation* 
Percent 
Friability* 
Percent assay* 
A1 11±0.25 7.3±0.18 1544±15.20 0.25±0.005 99.4±2.12 
A2 10.5±0.23  7.4±0.17 1540±10.14 0.14±0.004 99.5±2.15 
A3 10.5±0.19 7.3±0.17 1542±16.24 0.23±0.005 100.6±2.36 
A4 10.5±0.21 7.3±0.12 1541±20.25 0.18±0.003 101.4±1.98 
A5 11.0±0.20 7.3±0.15 1542±20.20 0.25±0.002 100.4±1.78 
A6 10.5±0.25 7.3±0.13 1540±19.36 0.25±0.005 99.2±2.14 
A7 11.0±0.24 7.3±0.16 1542±14.20 0.33±0.005 100.5±2.12 
A8 11.0±0.19 7.3±0.18 1545±18.20 0.21±0.007 99.8±3.12 
*n=6, mean ± SD 
Batch A2 gave maximum release compare to A3-A8 batches (A1 batch gave maximum release but it was >85 % at 8 hrs), and it 
also gave the same release profile as per in-house dissolution profile. Optimized batch A2 has passed all the specified range of 
parameter.  
Table 7: In-vitro dissolution profile of batches A1-A8 (bilayer tablet) 
Time 
(hrs.) 
Percent drug release 
A1 A2 A3 A4 A5 A6 A7 A8 
0.25 22.8 ±0.52 22.4 ±0.53 21.8 ±0.60 21.6 ±0.52 21.5 ±0.52 21.6 ±0.52 21.8 ±0.52 22.4 ±0.52 
1 39.8 ±0.52 32.4±1.92 29.5 ±0.81 36.1 ±0.65 35.7 ±0.59 36.1 ±0.53 36.1 ±0.78 38.3 ±0.72 
4 64.5±1.8 63.2 ±1.92 60.4 ±1.75 61.4 ±1.73 61.2 ±0.52 60.3 ±0.52 60.2 ±1.73 56.9 ±1.68 
8 85.7±1.8 83.2±1.3 80.7±1.6 79.8±2.8 79.3±2.6 78.7±1.6 78.3±2.5 77.9±1.6 
12 98.4 ±2.31 97.5 ±2.12 95.6 ±2.11 94.7 ±2.15 93.8 ±2.17 93.4 ±2.28 92.8 ±2.25 91.2 ±2.11 
n=6, mean ± SD 
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Pre-formulation study of batch A1-A8 batches of bilayer 
tablet was shown in Table 5 and which was the optimized for 
the further study because less than the above value then the 
tablet layer become separated during the friability study. 
Evaluation of bilayer tablets batches A1-A8 was depicted in 
Table 6. 
 
Figure 4: Drug dissolution profile of various developed 
formulations (SR1-SR8) 
DISCUSSION 
The aim of present investigation was the formulation 
development, evaluation and stability study of bilayer tablets 
of Citicoline sodium (CTS tablet). Optimized formulation 
design has been developed by using trail batches of CTS 
tablets. The amount of HPMC K100M and Ac-di-Sol were 
selected as factor for optimization. The DSC study depicted 
that no change in drug melting peak after the formulation 
with all other excipient. IR spectrum also concluded that no 
significant change in the peak of the citicoline sodium, which 
shown no interaction between drug and other excipient.  
Dissolution study of tablet has shown that the tablet by using 
the Ac-Di-Sol as a disintegrating agent shown better 
immediate release of drug as compare with the Sodium 
starch glycolate and could be retarded for 12 hrs; when 
release of citicoline achieved highest is kept at optimum 
level. So role of HPMC K 100 M polymer concentration is 
very important for IR formulation. Optimization formulation 
was further evaluated for the physical parameters and 
Micromeritic properties. 
In Case of SR layer incorporation of Citicoline (cerebral 
vasodilator agent) with inert HPMC K100 and Ac-Di-Sol 
(super disintegrating agent). HPMC and other polymer in 
different concentration were used to achieve sustained 
release kinetic for drug. There was no chemical interaction 
between the drug and polymers as inferred primarily from 
DSC and FTIR. Thus by HPMC K 100 M with MCC (pH 101) in 
solvent result in formation of thick gel which give diffusion 
path for drug and give control release profile. Hydroxy 
propyl methyl cellulose proved useful as a rate controlling 
polymer to produce a controlled release formulation of 
Citicoline using the diffusion-dissolution controlled 
mechanism. Hence, this optimized bi-layer tablet could be a 
potential formulation for delivery of drugs from a single 
dosage form which could improve patient compliance and 
give better disease management.  
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